Clinical Trials Logo

Primary Sjögren's Syndrome clinical trials

View clinical trials related to Primary Sjögren's Syndrome.

Filter by:

NCT ID: NCT00920179 Enrolling by invitation - Clinical trials for Primary Sjogren's Syndrome

Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome

Start date: October 2007
Phase: N/A
Study type: Observational

Traditional methodological clinical and instrumental diagnostics of the lacrimal gland for the study of glandular architecture and functions are limited and include analysis of tear constituents, evaluation of apparent diffusion coefficients in magnetic resonance imaging and histopathological evaluation of lacrimal gland biopsy specimens. Confocal microscopy is a new emerging technology which is useful as a supplementary diagnostic tool for in vivo assessment of anterior-segment disorders.The use of in vivo confocal microscopy in a comparative study of the microscopic morphology of the salivary/lacrimal glands have not been reported up to date. In this study, we employ laser scanning confocal microscopy to evaluate the morphological changes of the salivary/lacrimal glands in patients with primary Sjögren's syndrome and compare the results with those of healthy control subjects.

NCT ID: NCT00632866 Completed - Clinical trials for Primary Sjögren's Syndrome

Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome

JOQUER
Start date: March 2008
Phase: Phase 3
Study type: Interventional

Primary Sjögren's syndrome (SJp) affects 0.1% of the population. This systemic autoimmune disease systemic is characterized by disabling dryness, fatigue and pain, and systemic complications in 30% of patients. No treatment has proven effective in this disease. In open studies, some efficacy was observed with hydroxychloroquine but no RCT versus placebo has ever been done. Thus, the primary purpose of this study is to evaluate the efficacy and safety of hydroxychloroquine (400mg/ day) on dryness, pain, and fatigue, assessed by the patient using visual analogical scales.

NCT ID: NCT00542763 Completed - Clinical trials for Primary Sjogren's Syndrome

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

Start date: April 2005
Phase: Phase 1
Study type: Interventional

Primary Sjogren's syndrome (pSS) is an autoimmune disorder characterized by keratoconjunctivitis sicca and xerostomia. In addition, various extraglandular manifestations may develop. Several immunomodulating agents have been attempted in the treatment of pSS without achieving satisfactory results. Currently, there is no approved systemic treatment for pSS. Mycophenolic acid (MPA) is a selective inhibitor of inosine-monophosphate-dehydrogenase which leads to inhibition of the de novo pathway of nucleotide synthesis. The antiproliferative effect of MPA mainly affects activated T- and B-lymphocytes because the proliferation of these cells is critically dependent on the de novo purine synthesis compared to other eukaryotic cells. Since these lymphocytes have been suggested to play a pivotal role in the inflammation and immunopathogenesis of pSS, mycophenolate-sodium might be a promising agent in the treatment of pSS. We perform a single-centre, open-label pilot trial with Mycophenolate sodium in pSS.

NCT ID: NCT00426543 Completed - Fatigue Clinical Trials

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to determine whether B-cell depletion with Rituximab has an effect on the oral, ocular and general disease manifestations in patients with primary Sjögren´s syndrome, that is, an effect on the symptoms of oral and ocular dryness, improvement of the glandular function and a beneficial effect on the general symptoms such as fatigue. The secondary purpose of the study is the investigate the underlying autoimmune and pathophysiological mechanisms in Sjögren´s syndrome.